In April, Synpromics attended the 6th annual Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day in New York, a full-day conference featuring discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field’s most promising companies. Whilst there, David Venables, CEO of Synpromics, presented to potential investors and fellow biotech professionals.
Edinburgh, UK, 23rd April 2018 / Synpromics Ltd, the leader in gene control, announces a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals. The 18-month project has been made possible through the award of a £235,000 grant, part of the medicines manufacturing competition from Innovate UK.
As product developers move toward 2nd generation gene and cell medicine constructs, the importance of novel gene regulation and promoter elements has emerged. Synpromics is pleased to invite you to join them for a special symposium during the ASGCT Annual Meeting which will include presentations from Synpromics’ partners, an interactive panel discussion, and will be followed by a networking reception and refreshments. Please see the full agenda below.
Bringing synthetic biology to transcriptional regulation could catalyse a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. In a recent article for BioCentury Innovations, Karen Tkach Tuzman spoke to Dr Michael Roberts, CSO of Synpromics, about synthetic promoters and how Synpromics is using combinations of natural gene sequences to guide gene expression.